Stoke Therapeutics, Inc. Financing Cash Flow
Stoke Therapeutics, Inc. (STOK) reported Financing Cash Flow of $86.24 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-03
- Stoke Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $1.91M, a 245.13% increase year-over-year.
- Stoke Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $84.33M, a 6037.34% increase year-over-year.
- Stoke Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $92.34M, a 16157.22% increase year-over-year.
- Stoke Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $3.12M, a 61.76% decline year-over-year.
- Stoke Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $97.39M, a 25.71% decline from fiscal 2024.
- Stoke Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $131.09M, a 147.31% increase from fiscal 2023.
- Stoke Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $53.01M, a 14.22% increase from fiscal 2022.
- Stoke Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $46.41M, a 3514.41% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $86.24M 10-Q · filed 2026-08-03 | $178.58M derived: sum of 3 quarters · filed 2026-08-03 | $181.70M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $84.33M 10-Q · filed 2026-05-07 | $176.67M derived: sum of 2 quarters · filed 2026-05-07 | $179.79M derived: sum of 3 quarters · filed 2026-05-07 | $180.34M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $92.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $95.46M derived: sum of 2 quarters · filed 2026-03-16 | $96.02M derived: sum of 3 quarters · filed 2026-08-03 | $97.39M 10-K · filed 2026-03-16 |
| 2025-09-30 | $3.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $3.67M derived: sum of 2 quarters · filed 2026-08-03 | $5.05M 10-Q · filed 2025-11-04 | $5.62M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $554.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $1.93M 10-Q · filed 2026-08-03 | $2.50M derived: sum of 3 quarters · filed 2026-08-03 | $10.65M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $1.37M 10-Q · filed 2026-05-07 | $1.94M derived: sum of 2 quarters · filed 2026-05-07 | $10.10M derived: sum of 3 quarters · filed 2026-05-07 | $130.75M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $568.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $8.73M derived: sum of 2 quarters · filed 2026-03-16 | $129.38M derived: sum of 3 quarters · filed 2026-03-16 | $131.09M 10-K · filed 2026-03-16 |
| 2024-09-30 | $8.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $128.81M derived: sum of 2 quarters · filed 2025-11-04 | $130.53M 10-Q · filed 2025-11-04 | $137.87M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $120.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $122.37M 10-Q · filed 2025-08-12 | $129.71M derived: sum of 3 quarters · filed 2025-08-12 | $130.27M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $1.72M 10-Q · filed 2025-05-13 | $9.06M derived: sum of 2 quarters · filed 2025-05-13 | $9.62M derived: sum of 3 quarters · filed 2025-05-13 | $9.67M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $7.34M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $7.91M derived: sum of 2 quarters · filed 2025-03-18 | $7.95M derived: sum of 3 quarters · filed 2025-03-18 | $53.01M 10-K · filed 2025-03-18 |
| 2023-09-30 | $562.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $610.00K derived: sum of 2 quarters · filed 2024-11-05 | $45.66M 10-Q · filed 2024-11-05 | $45.71M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $48.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $45.10M 10-Q · filed 2024-08-07 | $45.15M derived: sum of 3 quarters · filed 2024-08-07 | $45.58M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $45.05M 10-Q · filed 2024-05-06 | $45.10M derived: sum of 2 quarters · filed 2024-05-06 | $45.53M derived: sum of 3 quarters · filed 2024-05-06 | $48.96M derived: sum of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | $43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $477.00K derived: sum of 2 quarters · filed 2024-03-25 | $3.90M derived: sum of 3 quarters · filed 2024-03-25 | $46.41M 10-K · filed 2024-03-25 |
| 2022-09-30 | $434.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $3.86M derived: sum of 2 quarters · filed 2023-11-07 | $46.37M 10-Q · filed 2023-11-07 | $46.54M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $3.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $45.93M 10-Q · filed 2023-08-07 | $46.10M derived: sum of 3 quarters · filed 2023-08-07 | $46.51M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $42.51M 10-Q · filed 2023-05-04 | $42.68M derived: sum of 2 quarters · filed 2023-05-04 | $43.09M derived: sum of 3 quarters · filed 2023-05-04 | $43.24M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $171.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $579.00K derived: sum of 2 quarters · filed 2023-03-06 | $738.00K derived: sum of 3 quarters · filed 2023-03-06 | $1.28M 10-K · filed 2023-03-06 |
| 2021-09-30 | $408.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $567.00K derived: sum of 2 quarters · filed 2022-11-14 | $1.11M 10-Q · filed 2022-11-14 | $107.98M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $159.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $705.00K 10-Q · filed 2022-08-08 | $107.57M derived: sum of 3 quarters · filed 2022-08-08 | $108.25M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $546.00K 10-Q · filed 2022-05-10 | $107.41M derived: sum of 2 quarters · filed 2022-05-10 | $108.09M derived: sum of 3 quarters · filed 2022-05-10 | $108.46M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $106.87M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $107.54M derived: sum of 2 quarters · filed 2022-03-10 | $107.91M derived: sum of 3 quarters · filed 2022-03-10 | $108.11M 10-K · filed 2022-03-10 |
| 2020-09-30 | $673.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $1.04M derived: sum of 2 quarters · filed 2021-11-08 | $1.24M 10-Q · filed 2021-11-08 | $1.43M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | $369.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $567.00K 10-Q · filed 2021-08-10 | $759.00K derived: sum of 3 quarters · filed 2021-08-10 | -$241.00K derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $198.00K 10-Q · filed 2021-05-10 | $390.00K derived: sum of 2 quarters · filed 2021-05-10 | -$610.00K derived: sum of 3 quarters · filed 2021-05-10 | $150.03M derived: sum of 4 quarters · filed 2021-05-10 |
| 2019-12-31 | $192.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | -$808.00K derived: sum of 2 quarters · filed 2021-03-09 | $149.83M derived: sum of 3 quarters · filed 2021-03-09 | $149.76M 10-K · filed 2021-03-09 |
| 2019-09-30 | -$1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $149.64M derived: sum of 2 quarters · filed 2020-11-12 | $149.57M 10-Q · filed 2020-11-12 | $239.35M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $150.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $150.57M 10-Q · filed 2020-08-10 | $240.35M derived: sum of 3 quarters · filed 2020-08-10 | $253.73M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | -$68.00K 10-Q · filed 2020-05-15 | $89.71M derived: sum of 2 quarters · filed 2020-05-15 | $103.09M derived: sum of 3 quarters · filed 2020-05-15 | |
| 2018-12-31 | $89.78M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-23 | $103.16M derived: sum of 2 quarters · filed 2020-03-23 | $115.64M 10-K · filed 2020-03-23 | |
| 2018-09-30 | $13.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $25.86M 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | $12.48M 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |